Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27765152 | 0.90 | POLB (0.51) | POLBSMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL1493809 | 0.81 | GAA (0.49) | POLBSMN1; SMN2LMNAALDH1A1HTT | |
| SCHEMBL9243189 | 0.77 | ALOX15 (0.47) | POLBSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL20346316 | 0.77 | SMN1; SMN2 (0.97) | POLBSMN1; SMN2LMNAALDH1A1TDP1 | |
| SCHEMBL9617817 | 0.76 | PARL (0.41) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL28659206 | 0.75 | ALOX15 (0.45) | POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL9243186 | 0.75 | ENPP3 (0.43) | SMN1; SMN2ALDH1A1KMT2ATDP1HPGD | |
| SCHEMBL12425968 | 0.75 | SMN1; SMN2 (1.00) | POLBSMN1; SMN2LMNAALDH1A1TDP1 | |
| SCHEMBL11747444 | 0.74 | POLB (0.44) | POLBSMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL28540250 | 0.74 | KDM4E (0.43) | SMN1; SMN2ALDH1A1KMT2ATDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915427-B2 | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2011-03-29 | — | — | US | claimed |
| US-20090048454-A1 | Process for Producing Aminoacetyl Pyrrolidine Carbonitrile Derivative and Intermediate for Production Thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2009-02-19 | — | — | US | claimed |
| EP-1995237-A1 | METHOD FOR PRODUCING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE AND PRODUCTION INTERMEDIATE THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2008-11-26 | — | — | EP | claimed |
| CN-101395131-B | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof | KYORIN SEIYAKU KK | 2012-11-14 | — | — | CN | disclosed |
| US-7915427-B2 | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| CN-101395131-A | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof | KYORIN SEIYAKU KK (JP) | 2009-03-25 | — | — | CN | disclosed |
| US-20090048454-A1 | Process for Producing Aminoacetyl Pyrrolidine Carbonitrile Derivative and Intermediate for Production Thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1995237-A1 | METHOD FOR PRODUCING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE AND PRODUCTION INTERMEDIATE THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048454-A1 | Process for Producing Aminoacetyl Pyrrolidine Carbonitrile Derivative and Intermediate for Production Thereof | CBR3, CPS1, CBR1 | POLB 3310/4885SMN1; SMN2 3794/4885LMNA 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.